我是新手,想买GNBT

白面包

今天8点的时候看到pre-market 0.65,
忽然起了0.13，可是又没有任何消息，
到底是哪个有钱人用0.65买呢？

木嘴

卡帖。。。。。。

m.i.k.e

gnbt,我会在五毛钱的价位等你哦...要不要成交,就看你的诚意了...

白面包

http://www.globenewswire.com/newsroom/news.html?d=169219

虽然是好消息，不过没有很大的波动。。
几个礼拜前看到google discussion有人说七月31会有share holder meeting
希望会起一两毛吧。。

Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer

WORCESTER, Mass., July 20, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today publication of studies demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine. The immunotherapeutic vaccine for HPV-induced cancers makes use of the Ii-Key platform technology developed by scientists at Antigen Express, Inc. (www.antigenexpress.com), Generex's wholly-owned immunotherapeutics subsidiary.

The results of the recent efforts appear in the journal Vaccine (Volume 27, Issue 34, July 2009) under the title "Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers." Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation.

The Antigen Express studies demonstrate that mice immunized with an Ii-Key/HPV16 E7 hybrid show increased killing of cells expressing an HPV-specific antigen, but not control cells lacking the antigen. Consistent with the predicted mechanism of action of the vaccine, HPV-specific activation of CD4+ T helper cells was observed in immunized mice. The first author of the study, Dr. Minzhen Xu, is Vice-President of Biology at Antigen Express.

The current studies demonstrate an additional application of the Ii-Key technology platform being developed at Antigen Express. Currently, another peptide designed with this technology is the subject of three clinical trials: a Phase II trial in breast cancer patients, a Phase I trial in prostate cancer patients, and a separate Phase I trial in breast or ovarian cancer patients wherein it is being tested in combination with another peptide vaccine. That immunotherapeutic vaccine, AE37, couples Ii-Key with a fragment of the HER2 protein, which is expressed in a variety of cancers and is associated with worse prognosis.

While prophylactic vaccines against HPV-induced cervical cancer are available, those vaccines do not benefit patients once cancer has arisen. The difference is that Ii-Key/HPV hybrid vaccines help to induce a cellular immune response, which is necessary for killing cancer cells.

In addition to developing immunotherapeutic vaccines for cancer, Antigen Express is also developing vaccines for infectious diseases, including the potentially pandemic H5N1 virus as well as the recent H1N1 pandemic virus. The fact that Antigen Express vaccines are manufactured by an entirely synthetic process, enabling rapid production of large amounts, makes them uniquely suited as a vaccine for pandemic or potentially pandemic viruses, given the supply limitations of more traditional vaccines.

葉芬

GNBT 昨晚AfterHour 0.73
不知是不是關于以下的消息。

http://www.globenewswire.com/newsroom/news.html?d=169219

Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer

WORCESTER, Mass., July 20, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today publication of studies demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine. The immunotherapeutic vaccine for HPV-induced cancers makes use of the Ii-Key platform technology developed by scientists at Antigen Express, Inc. (www.antigenexpress.com), Generex's wholly-owned immunotherapeutics subsidiary.

The results of the recent efforts appear in the journal Vaccine (Volume 27, Issue 34, July 2009) under the title "Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers." Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation.

The Antigen Express studies demonstrate that mice immunized with an Ii-Key/HPV16 E7 hybrid show increased killing of cells expressing an HPV-specific antigen, but not control cells lacking the antigen. Consistent with the predicted mechanism of action of the vaccine, HPV-specific activation of CD4+ T helper cells was observed in immunized mice. The first author of the study, Dr. Minzhen Xu, is Vice-President of Biology at Antigen Express.

The current studies demonstrate an additional application of the Ii-Key technology platform being developed at Antigen Express. Currently, another peptide designed with this technology is the subject of three clinical trials: a Phase II trial in breast cancer patients, a Phase I trial in prostate cancer patients, and a separate Phase I trial in breast or ovarian cancer patients wherein it is being tested in combination with another peptide vaccine. That immunotherapeutic vaccine, AE37, couples Ii-Key with a fragment of the HER2 protein, which is expressed in a variety of cancers and is associated with worse prognosis.

While prophylactic vaccines against HPV-induced cervical cancer are available, those vaccines do not benefit patients once cancer has arisen. The difference is that Ii-Key/HPV hybrid vaccines help to induce a cellular immune response, which is necessary for killing cancer cells.

In addition to developing immunotherapeutic vaccines for cancer, Antigen Express is also developing vaccines for infectious diseases, including the potentially pandemic H5N1 virus as well as the recent H1N1 pandemic virus. The fact that Antigen Express vaccines are manufactured by an entirely synthetic process, enabling rapid production of large amounts, makes them uniquely suited as a vaccine for pandemic or potentially pandemic viruses, given the supply limitations of more traditional vaccines. About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

原帖由 m.i.k.e 于 25-6-2009 07:55 AM 发表
gnbt,我会在五毛钱的价位等你哦...要不要成交,就看你的诚意了...

妳的GNBT買到了嗎？
近排妳的運氣不錯，每股給妳點到就飛。

[ 本帖最后由 葉芬 于 22-7-2009 10:18 AM 编辑 ]

白面包

原帖由 葉芬 于 22-7-2009 10:06 AM 发表
GNBT 昨晚AfterHour 0.73
不知是不是關于以下的消息。

http://www.globenewswire.com/newsroom/news.html?d=169219

Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for  ...

这个消息和20/7的那个是一样的。。。
GNBT 0.50的价位应该要等另外一个低潮吧。。
supporting line在0.54左右。。

葉芬

GNBT 爭氣點吧。
我等到鳥兒都飛了，還是些動靜都沒有。

巨大的西瓜

卡! 卡! 卡! 卡!